Skip to Content

Louise C. Strong, M.D.

Present Title & Affiliation

Primary Appointment

Professor, Department of Genetics, UTMDACC, Houston, TX
Professor, The University of Texas Graduate School of Biomedical Sciences, Houston, TX

Dual/Joint/Adjunct Appointment

Professor of Cancer Genetics, Department of Breast Medical Oncology, Division of Cancer Medicine, UTMDACC, Houston, TX

Research Interests

  • Human cancer genetics
  • Genetic epidemiology

The program involves the study of genetic etiology of human cancer using genetic epidemiologic approach to identify the most likely etiologic model(s) to account for the distribution of tumors in kindreds, and to test for genetic/etiologic heterogeneity. We then identify families in which a genetic etiology seems likely for collaborative study using cytogenetic, biochemical and molecular markers to localize the gene. We are further investigating the role of radiation, chemotherapy and host predisposing factors in the risk of subsequent tumors in childhood cancer survivors and in the reproductive outcomes in childhood cancer survivors.

A tutorial in this laboratory would include introduction to field work of data collection by interview, analytic techniques of genetic epidemiology and interpretation of laboratory findings from the collaborative laboratory studies.

View a complete list of Dr. Strong's publications.

Visit Dr. Strong’s Li Fraumeni Syndrome Study Group website.


Office Address

The University of Texas MD Anderson Cancer Center
Department of Genetics Unit 209
1515 Holcombe Blvd.
Houston, TX 77030
Room Number: B6.4806
Phone: (713) 792-2589

Education & Training

Degree-Granting Education

1970 University of Texas Medical Branch, Galveston, TX, MD, Medicine
1966 University of Texas, Austin, TX, BA, Mathematics

Postgraduate Training

9/1970-8/1972 Postdoctoral Fellowship, Texas Research Institute of Mental Sciences and The University of Texas Graduate School of Biomedical Sciences, Houston, TX, Alfred G. Knudson Jr., M.D., Ph.D.

Selected Publications

Peer-Reviewed Original Research Articles

1. Palculict TB, Ruteshouser EC, Fan Y, Wang W, Strong LC, Huff V. Identification of germline DICER1 mutations and loss of heterozygosity in familial Wilms tumor using whole genome sequencing. J Med Genet 53(6):385-8, 6/2016. PMID: 26566882.
2. Malkin D, Garber JE, Strong LC, Friend SH. CANCER. The cancer predisposition revolution. Science 352(6289):1052-3, 5/2016. PMID: 27230363.
3. Meric-Bernstam F, Brusco L, Daniels M, Wathoo C, Bailey AT, Strong LC, Shaw K, Lu K, Qi Y, Lara-Guerra H, Litton J, Arun B, Zhao H, Eterovic AK, Aytac U, Routbort M, Subbiah V, Janku F, Davies D, Kopetz S, Mendelsohn J, Mills GB, Chen K. Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol. Annals of Oncology 27(5):795-800, 5/2016.
4. Henderson TO, Moskowitz CS, Chou J, Bradbury AR, Neglia JP, Dang CT, Onel K, Friedman DN, Bhatia S, Strong LC, Stovall M, Kenney LB, Barnea D, Lorenzi E, Hammond S, Leisenring W, Robison LL, Armstrong GT, Diller LR, Oeffinger K. Breast cancer risk in childhood cancer survivors without a history of chest radiotherapy: A report from the Childhood Cancer Survivor Study (CCSS). J Clin Oncol 34(9):910-918, 3/2016. PMCID: PMC4871997.
5. Yang XR, Killian JK, Hammond S, Burke LS, Bennett H, Wang Y, Davis SR, Strong LC, Neglia J, Stovall M, Weathers RE, Robison LL, Bhatia S, Mabuchi K, Inskip PD, Meltzer P. Characterization of genomic alterations in radiation-associated breast cancer among childhood cancer survivors, using comparative genomic hybridization (CGH) arrays. PLoS One 10(3):e0116078, 3/2015. e-Pub 3/2015. PMCID: PMC4357472.
6. Cozen W, Timofeeva MN, Li D, Diepstra A, Hazelett D, Delahaye-Sourdeix M, Edlund CK, Franke L, Rostgaard K, Van Den Berg DJ, Cortessis VK, Smedby KE, Glaser SL, Westra HJ, Robison LL, Mack TM, Ghesquieres H, Hwang AE, Nieters A, de Sanjose S, Lightfoot T, Becker N, Maynadie M, Foretova L, Roman E, Benavente Y, Rand KA, Nathwani BN, Glimelius B, Staines A, Boffetta P, Link BK, Kiemeney L, Ansell SM, Bhatia S, Strong LC, Galan P, Vatten L, Habermann TM, Duell EJ, Lake A, Veenstra RN, Visser L, Liu Y, Urayama KY, Montgomery D, Gaborieau V, Weiss LM, Byrnes G, Lathrop M, Cocco P, Best T, Skol AD, Adami HO, Melbye M, Cerhan JR, Gallagher A, Taylor GM, Slager SL, Brennan P, Coetzee GA, Conti DV, Onel K, Jarrett RF, Hjalgrim H, van den Berg A, McKay JD. A meta-analysis of Hodgkin lymphoma reveals 19p13.3 TCF3 as a novel susceptibility locus. Nat Commun 5:3856, 6/2014. PMCID: PMCPMC4055950.
7. Hill DA, Horick NK, Isaacs C, Domchek SM, Tomlinson GE, Lowery JT, Kinney AY, Berg JS, Edwards KL, Moorman PG, Plon SE, Strong LC, Ziogas A, Griffin CA, Kasten CH, Finkelstein DM. Long-term risk of medical conditions associated with breast cancer treatment. Breast Cancer Res Treat 145(1):233-43, 5/2014. PMCID: PMCPMC4096572.
8. Gramatges MM, Liu Q, Yasui Y, Okcu MF, Neglia JP, Strong LC, Armstrong GT, Robison LL, Bhatia S. Telomere content and risk of second malignant neoplasm in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. Clin Cancer Res 20(4):904-11, 2/2014. e-Pub 11/2013. PMCID: PMCPMC3944671.
9. Pilarski R, Cebulla CM, Massengill JB, Rai K, Rich T, Strong LC, McGillivray B, Asrat M-J, Davidorf FH, Abdel-Rahman MH. Expanding the clinical phenotype of hereditary BAP1 cancer predisposition syndrome. Genes Chromosomes Cancer 53(2):177–182, 1/2014. PMCID: PMC4041196.
10. Powell BC, Jiang L, Muzny DM, Trevino L, Dreyer Z, Strong LC, Wheeler DA,. Gibbs RA, Plon SE. Identification of TP53 as an acute lymphocytic leukemia susceptibility gene through exome sequencing. Pediatr Blood Cancer 60(6):E1-3153, 6/2013. PMCID: PMC3926299.
11. Fang S, Krahe R, Bachinski LL, Zhang B, Amos CI, Strong LC. Sex-specific effect of TP53 PIN3 polymorphism on cancer risk in a cohort study of TP53 germline mutation carriers. Hum Genet 130(6):789-94, 12/2011. e-Pub 6/19/2011. PMID: 21688173.
12. Wu, CC, Krahe R, Lozano G, Zhang B, Wilson CD, Jo EJ, Shete S, Amos CI, Strong LC. Joint effects of germ-line TP53 mutation, MDM2 SNP309, and gender on cancer risk in family studies of Li-Fraumeni syndrome. Hum Genet 129(6):663-73, 6/2011. PMID: 21305319.
13. Fang, S, Krahe R, Lozano G, Han Y, Chen W, Post SM, Zhang B, Wilson C, Bachinski LL, Strong LC, Amos CI. Effects of MDM2, MDM4 and TP53 codon 72 polymorphisms on cancer risk in carriers of TP53 germline mutations. PLoS ONE 5(5):e10813, 5/2010. PMCID: PMCPMC2877078.
14. Wu CC, Strong LC, Shete S.. Effects of measured susceptibility genes on cancer risk in family studies. Hum Genet 127(3):349-357, 3/2010. PMCID: PMCPMC2918266.
15. Peterson SK, Pentz RD, Marani SK, Ward PA, Blanco AM, LaRue D, Vogel K, Solomon T, Strong LC. Psychological functioning in persons considering genetic counseling and testing for Li-Fraumeni syndrome. Psychooncology 17(8):783-789, 8/2008. PMID: 18688785.
16. Peterson SK, Pentz RD, Blanco AM, Ward PA, Watts BG, Marani SK, James LC, Strong LC. Evaluation of a decision aid for families considering p53 genetic counseling and testing. Genet Med 8(4):226-33, 4/2006. PMID: 16617243.
17. Li FP, Garber JE, Friend SH, Strong LC, Patenaude AF, Juengst ET, Reilly PR, Correa P, Fraumeni JF, Jr. Recommendations on predictive testing for germ line p53 mutations among cancer-prone individuals. J Natl Cancer Inst 84(15):1156-60, 8/1992. PMID: 1635084.

Letters to the Editor

1. Tefferi A, Kantarjian H, Rajkumar SV, Baker LH, Abkowitz JL, Adamson JW, Advani RH, Allison J, Antman KH, Bast RC Jr, Bennett JM, Benz EJ Jr, Berliner N, Bertino J, Bhatia R, Bhatia S, Bhojwani D, Blanke CD, Bloomfield CD, Bosserman L, Broxmeyer HE, Byrd JC, Cabanillas F, Canellos GP, Chabner BA, Chanan-Khan A, Cheson B, Clarkson B, Cohn SL, Colon-Otero G, Cortes J, Coutre S, Cristofanilli M, Curran WJ Jr, Daley GQ, DeAngelo DJ, Deeg HJ, Einhorn LH, Erba HP, Esteva FJ, Estey E, Fidler IJ, Foran J, Forman S, Freireich E, Fuchs C, George JN, Gertz MA, Giralt S, Golomb H, Greenberg P, Gutterman J, Handin RI, Hellman S, Hoff PM, Hoffman R, Hong WK, Horowitz M, Hortobagyi GN, Hudis C, Issa JP, Johnson BE, Kantoff PW, Kaushansky K, Khayat D, Khuri FR, Kipps TJ, Kripke M, Kyle RA, Larson RA, Lawrence TS, Levine R, Link MP, Lippman SM, Lonial S, Lyman GH, Markman M, Mendelsohn J, Meropol NJ, Messinger Y, Mulvey TM, O'Brien S, Perez-Soler R, Pollock R, Prchal J, Press O, Radich J, Rai K, Rosenberg SA, Rowe JM, Rugo H, Runowicz CD, Sandmaier BM, Saven A, Schafer AI, Schiffer C, Sekeres MA, Silver RT, Siu LL, Steensma DP, Stewart FM, Stock W, Stone R, Storb R, Strong LC, Tallman MS, Thompson M, Ueno NT, Van Etten RA, Vose JM, Wiernik PH, Winer EP, Younes A, Zelenetz AD, LeMaistre CA. In support of a patient-driven initiative and petition to lower the high price of cancer drugs. Mayo Clin Proc S0025-6196(15):00430-9, 8/2015. PMID: 26211600.
2. Leroy B, Strong LC, Soussi T. Revised guidelines for screening of TP53 gene mutations. Nature Rev Clin Oncol. Submitted.

Last updated: 9/8/2016